Amgen (NASDAQ:AMGN) Shares Purchased Rep. Marjorie Taylor Greene

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on May 19th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on May 14th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 5/16/2025.
• Purchased $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 5/14/2025.
• Purchased $1,001 – $15,000 in shares of Impinj (NASDAQ:PI) on 5/14/2025.
• Purchased $1,001 – $15,000 in shares of Corning (NYSE:GLW) on 5/14/2025.
• Purchased $1,001 – $15,000 in shares of Cardinal Health (NYSE:CAH) on 5/14/2025.
• Purchased $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 5/14/2025.
• Purchased $15,001 – $50,000 in shares of UnitedHealth Group (NYSE:UNH) on 5/14/2025.
• Purchased $1,001 – $15,000 in shares of Blackstone (NYSE:BX) on 5/14/2025.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 5/14/2025.
• Purchased $1,001 – $15,000 in shares of Hershey (NYSE:HSY) on 5/14/2025.

Amgen Price Performance

AMGN stock opened at $275.01 on Wednesday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The stock has a market cap of $147.87 billion, a price-to-earnings ratio of 36.43, a P/E/G ratio of 2.63 and a beta of 0.51. The company has a 50 day simple moving average of $289.51 and a 200 day simple moving average of $287.47.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.96 earnings per share. Research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.46%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 86.86%.

Institutional Trading of Amgen

Hedge funds have recently bought and sold shares of the business. Focus Partners Wealth raised its stake in Amgen by 17.9% in the 1st quarter. Focus Partners Wealth now owns 221,488 shares of the medical research company’s stock valued at $69,006,000 after acquiring an additional 33,626 shares during the period. Integrity Alliance LLC. increased its holdings in shares of Amgen by 66.2% in the first quarter. Integrity Alliance LLC. now owns 8,436 shares of the medical research company’s stock worth $2,628,000 after buying an additional 3,359 shares during the period. Ransom Advisory Ltd bought a new stake in Amgen in the 1st quarter worth $580,000. Advisory Alpha LLC grew its position in shares of Amgen by 12.2% in the 1st quarter. Advisory Alpha LLC now owns 919 shares of the medical research company’s stock worth $286,000 after buying an additional 100 shares during the last quarter. Finally, Bayforest Capital Ltd bought a new stake in Amgen during the 1st quarter valued at approximately $41,000. 76.50% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP David M. Reese sold 25,225 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares of the company’s stock, valued at $11,240,533.68. This trade represents a 40.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.76% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald began coverage on Amgen in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $305.00 price target for the company. UBS Group restated a “neutral” rating and set a $315.00 price target (down from $319.00) on shares of Amgen in a report on Friday, May 2nd. Erste Group Bank lowered shares of Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Morgan Stanley reiterated an “equal weight” rating on shares of Amgen in a research report on Friday, May 2nd. Finally, Mizuho raised their price target on shares of Amgen from $235.00 to $280.00 and gave the stock a “neutral” rating in a report on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Amgen currently has an average rating of “Hold” and an average price target of $309.22.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.